Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

“Breakthrough” Review: FDA And Sponsors Discuss Ways To Improve Efficiency

Executive Summary

Pharmacyclics exec says PDUFA V “program” meetings should be optional, as timelines for mid-cycle communication and late-cycle meeting are out of sync with highly compressed review times for some products. CDER is internally discussing whether it would be feasible to give breakthrough therapy sponsors a target date for approval.

You may also be interested in...



Gottlieb Promotes 'Bottom-Up' Review To Increase FDA Efficiency, Consistency

US FDA commissioner nominee suggests breakthrough concepts should be more widely adopted within the review divisions and that staff should find and distribute best practices.

PDUFA V 'Program' First-Cycle Approval Rates Significantly Higher For All Applications

Success of review model for new molecular entities and novel biologics should bolster US FDA and industry's stance that Congress reauthorize the user fee program without tinkering with the negotiated agreement, which retains the 'Program' but builds in more flexibility.

FDA ‘Expedited Review’ Would Shave Off Additional Month For Some ‘Breakthrough’ Products

FDA appears to be establishing new regulatory paradigm – albeit one that is not laid out in statute officially.

Related Content

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

PS056107

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel